These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 3799213)

  • 21. Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes.
    Sun W; Zhang N; Li A; Zou W; Xu W
    Int J Pharm; 2008 Apr; 353(1-2):243-50. PubMed ID: 18155370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
    Tzioumaki N; Manta S; Tsoukala E; Vande Voorde J; Liekens S; Komiotis D; Balzarini J
    Eur J Med Chem; 2011 Apr; 46(4):993-1005. PubMed ID: 21330014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gas chromatographic-mass fragmentographic determination of 5-fluorouracil as a metabolite of new 5-fluorouracil derivatives.
    Marunaka T; Umeno Y
    Chem Pharm Bull (Tokyo); 1982 May; 30(5):1868-71. PubMed ID: 7116517
    [No Abstract]   [Full Text] [Related]  

  • 24. [Synthesis and antitumor activity of new heterocyclic 5-fluorouracil derivatives].
    Mao M; Chen Y; Tian X
    Yao Xue Xue Bao; 1998 May; 33(5):389-91. PubMed ID: 12017008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and antitumor activity of 5-fluorouracil derivatives.
    Ozaki S
    Med Res Rev; 1996 Jan; 16(1):51-86. PubMed ID: 8788214
    [No Abstract]   [Full Text] [Related]  

  • 26. [Synthesis and study of the antitumor activity of glucuronide derivatives of 5-fluorouracil].
    Carissimi M; de Meglio P; Gentili P; Ravenna F
    Boll Chim Farm; 1979 Dec; 118(12):721-8. PubMed ID: 552254
    [No Abstract]   [Full Text] [Related]  

  • 27. Combined environmental risk assessment for 5-fluorouracil and capecitabine in Europe.
    Straub JO
    Integr Environ Assess Manag; 2010 Jul; 6 Suppl():540-66. PubMed ID: 19958049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Drug exanthema caused by a new 5-fluorouracil derivative].
    Ueki H; Namba M
    Hautarzt; 1980 Apr; 31(4):207-8. PubMed ID: 6772600
    [No Abstract]   [Full Text] [Related]  

  • 29. Hydrolysis of and transormation between N-phenyl-2-oxazolidones and 2-benzoxazolinones.
    Brånstad JO; Ekberg G; Nilsson JL; Selander H; Stenberg P
    Acta Pharm Suec; 1972 Nov; 9(5):475-90. PubMed ID: 4650124
    [No Abstract]   [Full Text] [Related]  

  • 30. Development of absorption furosemide prodrugs: synthesis, in vitro and in vivo evaluation.
    Prandi C; Fagiolino P; Manta E; Llera LD; Aiache JM; Couquelet J
    Farmaco; 1992 Feb; 47(2):249-63. PubMed ID: 1510797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-fluorouracil.
    IARC Monogr Eval Carcinog Risk Chem Hum; 1981 May; 26():217-35. PubMed ID: 6944260
    [No Abstract]   [Full Text] [Related]  

  • 32. 30 years of 5-fluorouracil.
    Wasternack C; Hause B
    Pharmazie; 1987 Feb; 42(2):73-9. PubMed ID: 3602063
    [No Abstract]   [Full Text] [Related]  

  • 33. A new method for the synthesis of N3-alkylated analogs of 5-fluorouracil.
    Kozai S; Fukagawa T; Maruyama T
    Nucleic Acids Symp Ser; 1999; (42):3-4. PubMed ID: 10780350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relation between chemical structure and physicochemical and pharmacokinetic properties of various benzodiazepines].
    Fernández Gómez P; Vila Jato JL
    Arch Farmacol Toxicol; 1984 Dec; 10(3):199-204. PubMed ID: 6532326
    [No Abstract]   [Full Text] [Related]  

  • 35. Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol.
    Kaneniwa N; Otsuka M; Hayashi T
    Chem Pharm Bull (Tokyo); 1985 Aug; 33(8):3447-55. PubMed ID: 4085076
    [No Abstract]   [Full Text] [Related]  

  • 36. THE MODE OF ACTION OF 5-FLUOROURACIL AND ITS DERIVATIVES.
    Cohen SS; Flaks JG; Barner HD; Loeb MR; Lichtenstein J
    Proc Natl Acad Sci U S A; 1958 Oct; 44(10):1004-12. PubMed ID: 16590300
    [No Abstract]   [Full Text] [Related]  

  • 37. On Complex Formation between 5-Fluorouracil and β-Cyclodextrin in Solution and in the Solid State: IR Markers and Detection of Short-Lived Complexes by Diffusion NMR.
    Melnikova DL; Badrieva ZF; Kostin MA; Maller C; Stas M; Buczek A; Broda MA; Kupka T; Kelterer AM; Tolstoy PM; Skirda VD
    Molecules; 2020 Dec; 25(23):. PubMed ID: 33287255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical Delivery of 5-Fluorouracil from Pheroid™ Formulations and the In Vitro Efficacy Against Human Melanoma.
    Chinembiri TN; Gerber M; du Plessis L; du Preez J; du Plessis J
    AAPS PharmSciTech; 2015 Dec; 16(6):1390-9. PubMed ID: 25956486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioavailability enhancers of herbal origin: an overview.
    Kesarwani K; Gupta R; Mukerjee A
    Asian Pac J Trop Biomed; 2013 Apr; 3(4):253-66. PubMed ID: 23620848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure of 3-acetyl-5-fluorouracil (5-FU): implication for its rearrangements during hydrolysis and upon heating.
    Beall HD; Prankerd RJ; Todaro LJ; Sloan KB
    Pharm Res; 1993 Jun; 10(6):905-12. PubMed ID: 8321861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.